Enrolling By Invitation PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT06763965

A Clinical Study Evaluating the Safety and Efficacy of BioTTT001 in Patients With Recurrent/Progressive High-grade Glioma.

A Phase Ib/Ⅱ Clinical Study to Evaluate the Safety, Tolerability, Biodistribution Characteristics and Preliminary Efficacy of Recombinant Human nsIL12 Oncolytic Adenovirus Injection (BioTTT001) in Patients With Recurrent/Progressive High-grade Glioma.

Sponsor: Beijing Bio-Targeting Therapeutics Technology Co., Ltd

Conditions Recurrent High-grade Glioma

Interventions BioTTT001 injection

Updated 2 times since 2025 Last updated: Nov 25, 2025 Started: Nov 26, 2024 Primary completion: Jul 31, 2027 Completion: Jul 31, 2027

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1/PHASE2 trial investigates Recurrent High-grade Glioma and is currently ongoing. Beijing Bio-Targeting Therapeutics Technology Co., Ltd leads this study, which shows 2 recorded versions since 2024 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

2 versions recorded

Jan 2026 — Present [monthly]

Enrolling By Invitation PHASE1/PHASE2
Feb 2025 — Jan 2026 [monthly]

Enrolling By Invitation PHASE1/PHASE2

First recorded

Nov 2024

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Beijing Bio-Targeting Therapeutics Technology Co., Ltd

Data source: Beijing Bio-Targeting Therapeutics Technology Co., Ltd

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Beijing, China